Singh, Jasvinder A. http://orcid.org/0000-0003-3485-0006
Cleveland, John D.
Funding for this research was provided by:
Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham (No number)
the resources and use of facilities at the Birmingham Veterans Affairs medical center (No number)
Article History
Received: 7 March 2018
Accepted: 24 April 2018
First Online: 1 June 2018
Ethics approval and consent to participate
: The University of Alabama at Birmingham’s Institutional Review Board approved this study and all investigations were conducted in conformity with ethical principles of research. The IRB waived the need for informed consent for this database study.
: JAS has received research grants from Takeda and Savient and consultant fees from Savient, Takeda, Regeneron, Merz, Iroko, Bioiberica, Fidia, Crealta/Horizon and Allergan pharmaceuticals, WebMD, UBM LLC, and National Institute of Health and the American College of Rheumatology. JAS serves as the principal investigator for an investigator-initiated study funded by Horizon pharmaceuticals through a grant to DINORA, Inc., a 501 (c)(3) entity. JAS is a member of the executive of OMERACT, an organization that develops outcome measures in rheumatology and receives arms-length funding from 36 companies; a member of the American College of Rheumatology’s (ACR) Annual Meeting Planning Committee (AMPC); Chair of the ACR Meet-the-Professor, Workshop and Study Group Subcommittee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee. JAS is the editor and Director of the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis. JDC has no relevant financial conflicts. There are no nonfinancial competing interests for either author.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.